Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108
Sponsor: Novo Nordisk A/S
Summary
The study looks at the safety and blood levels of the study drug INV-347 in participants who were previously dosed with INV-347 in study INV-CL-108. Participants will not get any study drug in this study as it looks into the safety of a drug previously dosed. The study will last until visit 21.
Official title: Safety Follow-up Study of Participants Previously Dosed With INV-347 in the First-in-Human Study INV-CL-108
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
91
Start Date
2025-08-06
Completion Date
2027-09-15
Last Updated
2026-03-06
Healthy Volunteers
Yes
Conditions
Interventions
INV-347
Participants who were dosed with INV-347 in the First In Human study INV-CL-108 and still have measurable plasma exposure of INV-347 are included to assess long term safety.
Locations (1)
Syneos Health Clinique
Québec, Canada